Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025350 · ClinicalTrials.gov registry record · Phase 2
Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer
A Phase 2 study of Colorectal Cancer, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Study locations
NCT00025350: Completed Phase 2 study of Colorectal Cancer, sponsored by Eastern Cooperative Oncology Group.
NCT00025350 is a Phase 2 study of Colorectal Cancer that has completed, run by Eastern Cooperative Oncology Group. The trial reports 16 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025350, a Phase 2 study of Colorectal Cancer, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16
- Study locations
Study Summary
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of recurrent metastatic colorectal cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of two different doses of gefitinib in treating patients who have recurrent metastatic colorectal cancer.
Conditions Studied
Interventions
- DRUG gefitinib
Study Locations (16)
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
- Veterans Affairs Medical Center - Lakeside Chicago - Chicago
- CCOP - Central Illinois - Decatur
- CCOP - Evanston - Evanston
New York
- Veterans Affairs Medical Center - New York - New York
- NYU School of Medicine's Kaplan Comprehensive Cancer Center - New York
Pennsylvania
- University of Pennsylvania Cancer Center - Philadelphia
- University of Pittsburgh Cancer Institute - Pittsburgh
Tennessee
- Veterans Affairs Medical Center - Tennessee Valley Healthcare System - Nashville Campus - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Wisconsin
- Veterans Affairs Medical Center - Madison - Madison
- University of Wisconsin Comprehensive Cancer Center - Madison
Michigan
- CCOP - Kalamazoo - Kalamazoo
New Jersey
- Cancer Institute of New Jersey - New Brunswick
North Dakota
- CCOP - Merit Care Hospital - Fargo
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-10 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
What the finished NCT00025350 record still lists
NCT00025350 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which gefitinib is the first listed.
NCT00025350 lists 16 locations in 9 states (Illinois, New York, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT00025350 about?
NCT00025350 is a clinical study titled "Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer". RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of recurrent metastatic colorectal cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of two different doses of gefitinib in treating patients who have recurre...
What is the current status of trial NCT00025350?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-10. Estimated completion is 2006-06.
What conditions does trial NCT00025350 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT00025350?
The interventions under investigation include: gefitinib (DRUG).
Who is sponsoring clinical trial NCT00025350?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00025350 being conducted?
This trial has 16 study locations across Illinois, Michigan, New Jersey, New York, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia